Welcome to Browse Page of Biomarker

This page shows the result of browsing biomarker from different fieldss.For more information see HELP page.

The total number entries retrieved from this search are 46
Please click on Biomarker_ID to view detailed information.
Note: Potential Biomarker with * indicates these signatures are candidate biomarkers extracted from experiments on mice, rat or cell lines and they are not validated on human patients'cohort.
Biomarker IDBiomarkerBiomoleculeSubjectRegulationBiomarker's typeExperimentLevel of significanceSourcePMID
2018miR-375miRNAHumanDownregulated in Cancer Diagnostic and PrognosticLiver cancer v/s Normal p < 0.01Tissue28781668
2019miR-221miRNAHumanUpregulated in Cancer Diagnostic and PrognosticLiver cancer v/s Normal p < 0.01Tissue28781668
2025miR-34a-5pmiRNASprague- Dawley rats Upregulated in TAA-induced hepatocarcinogenesis (with Log fold change more than 1.5 to 4.7) Potential Diagnostic and Prognostic *Control Sprague-Dawley rats and rats treated with TAA at three doses; can predict early HCC p < 0.05Tissue28596526
2026miR-455-3pmiRNASprague- Dawley rats Downregulated in TAA-induced hepatocarcinogenesis Potential Diagnostic and Prognostic *Control Sprague-Dawley rats and rats treated with TAA at three doses; can predict early HCC p < 0.05Tissue28596526
2089miR-200cmiRNAHumanDownregulated in PSC with control DiagnosticNormal v/s cancer v/s PSC p < 0.05Serum26864161
2090miR-483-5pmiRNAHumanUpregulated in CC compared with controls and PSC. DiagnosticNormal vs cancer p < 0.05Serum26864161
2091miR-194miRNAHumanUpregulated in CC compared with controls. DiagnosticNormal vs cancer p < 0.05Serum26864161
2093miR-122miRNAHumanUpregulatd in chronic HCV v/s healthy control (with log fold change 3.17) DiagnosticCancer v/s Normal p < 0.05Serum26812693
2094miR-222miRNAHumanUpregulatd in chronic HCV v/s healthy control (with log fold change 3.11) DiagnosticCancer v/s Normal p < 0.01Serum26812693
2116miR-128-2miRNAHumanUpregulated in HCC tissues PrognosticHCC v/s Normal, predict survival of patients p < 0.01Serum25642945
2118HNF4A, RelAmiRNAHumanupregulated in hepatoma cells PrognosticL-HNF4α group v/s hig-HNF4α group; associated with survival of patients p < 0.05Tissue24752868
2133miR-1miRNAHumanIncreasead concentration showed longer OS in HCC PrognosticHCC v/s Liver Cirrhosis; predict survival of patients p < 0.01Serum23810247
2140miR-18b*miRNAHumanDownregulated in the HCC v/s non-tumor (with fold change 0.21) DiagnosticNormal v/s HCC/HCV/HBV p < 0.001Tissue23205106
2141miR-296-5pmiRNAHumanDownregulated in the HCC v/s non-tumor (with fold change 0.16) DiagnosticNormal v/s HCC/HCV/HBV p < 0.001Tissue23205106
2142miR-557miRNAHumanDownregulated in the HCC v/s non-tumor (with fold change 0.29) DiagnosticNormal v/s HCC/HCV/HBV p < 0.01Tissue23205106
2143miR-581miRNAHumanDownregulated in the HCC v/s non-tumor (with fold change 0.10) DiagnosticNormal v/s HCC/HCV/HBV p < 0.01Tissue23205106
2144miR-625*miRNAHumanDownregulated in the HCC v/s non-tumor (with fold change 0.23) DiagnosticNormal v/s HCC/HCV/HBV p < 0.01Tissue23205106
2145miR-1228miRNAHumanDownregulated in the HCC v/s non-tumor (with fold change 0.30) DiagnosticNormal v/s HCC/HCV/HBV p < 0.01Tissue23205106
2146miR-1249miRNAHumanDownregulated in the HCC v/s non-tumor (with fold change 0.20) DiagnosticNormal v/s HCC/HCV/HBV p < 0.001Tissue23205106
2147miR-2116*miRNAHumanDownregulated in the HCC v/s non-tumor (with fold change 0.048) DiagnosticNormal v/s HCC/HCV/HBV p < 0.05Tissue23205106
2148miR-129*miRNAHumanDownregulated in the HCC v/s non-tumor DiagnosticNormal vs HCC, liver cancer p < 0.05Tissue23205106
2149miR-146b-3pmiRNAHumanDownregulated in the HCC v/s non-tumor DiagnosticNormal vs HCC, liver cancer p < 0.05Tissue23205106
2150miR-448miRNAHumanDownregulated in the HCC v/s non-tumor DiagnosticNormal vs HCC, liver cancer p < 0.05Tissue23205106
2160miR-515-3pmiRNAHumanUpregulated in HCC PrognosticHCC v/s other liver disease (cirrhosis/dysplasia); predict survival and recurrence of patients p < 0.01Tissue22429613
2161miR-518a-3pmiRNAHumanUpregulated in HCC PrognosticHCC v/s other liver disease (cirrhosis/dysplasia); predict survival and recurrence of patients p < 0.01Tissue22429613
2162miR-520fmiRNAHumanUpregulated in HCC PrognosticHCC v/s other liver disease (cirrhosis/dysplasia); predict survival and recurrence of patients p < 0.01Tissue22429613
2163miR-525-3pmiRNAHumanUpregulated in HCC PrognosticHCC v/s other liver disease (cirrhosis/dysplasia); predict survival and recurrence of patients p < 0.01Tissue22429613
2178miR-122miRNAHumanvariable expression between different hepatoma cell lines: PLC/PRF/5, Huh-1, and Hep40 exhibited very high levels of miR-122, whereas others, such as Hep3B and HepG2, expressed little or did not express miR-122 at all (e.g. SNU387, and SNU398) ; in HCC patients miR-122 was specifically repressed in Diagnostic and PrognosticNormal vs HCC; associated with survival, tumor size and differentiation status p < 0.001Tissue and Cells 19617899
2181miR-101-3p, miR-106b-3p, miR-1246miRNAHumanUpregulated in HCC DiagnosticHCC v/s Cirrhosis p < 0.001Plasma29632649
2182miR-101-3pmiRNAHumanUpregulated in HCC DiagnosticHCC v/s Cirrhosis p < 0.001Plasma29632649
2183miR-1246miRNAHumanUpregulated in HCC DiagnosticHCC v/s Cirrhosis p < 0.001Plasma29632649
2184miR-106b-3pmiRNAHumanUpregulated in HCC DiagnosticHCC v/s Cirrhosis p < 0.001Plasma29632649
2185miR-101-3p, miR-106b-3pmiRNAHumanUpregulated in HCC DiagnosticHCC v/s Cirrhosis p < 0.001Plasma29632649
2186miR-101-3p, miR-1246miRNAHumanUpregulated in HCC DiagnosticHCC v/s Cirrhosis p < 0.001Plasma29632649
2187miR-106b-3p, miR-1246miRNAHumanUpregulated in HCC DiagnosticHCC v/s Cirrhosis p < 0.001Plasma29632649
2188miR-101-3pmiRNAHumanUpregulated in HCC DiagnosticHCC v/s Control p < 0.001Plasma29632649
2189miR-101-3p, miR-106b-3p, miR-1246miRNAHumanUpregulated in HCC DiagnosticHCC v/s Control p < 0.001Plasma29632649
2190miR-1246miRNAHumanUpregulated in HCC DiagnosticHCC v/s Control p < 0.001Plasma29632649
2191miR-106b-3pmiRNAHumanUpregulated in HCC DiagnosticHCC v/s Control p < 0.001Plasma29632649
2192miR-101-3p, miR-106b-3pmiRNAHumanUpregulated in HCC DiagnosticHCC v/s Control p < 0.001Plasma29632649
2193miR-101-3p, miR-1246miRNAHumanUpregulated in HCC DiagnosticHCC v/s Control p < 0.001Plasma29632649
2194miR-106b-3p, miR-1246miRNAHumanUpregulated in HCC DiagnosticHCC v/s Control p < 0.001Plasma29632649
2195miR-101-3pmiRNAHumanUpregulated in HCC DiagnosticHCC v/s Cirrhosis p < 0.001Serum29632649
2196miR-106b-3pmiRNAHumanUpregulated in HCC DiagnosticHCC v/s Cirrhosis p < 0.001Serum29632649
2197miR-101-3p, miR-106b-3pmiRNAHumanUpregulated in HCC DiagnosticHCC v/s Cirrhosis p < 0.001Serum29632649
2198miR-26amiRNAHuman cell lineDownregulated in HepG2 cells Potential Diagnostic *Normal cell line vs Liver cancer cell line p < 0.05Cells29430178

         Raghava's group    CancerCSP    CancerSPP    CancerPDF    CancerTSP    CancerLSP    HCCPred   

Scroll to Top